Literature DB >> 4318252

Initial toxicity study of sangivamycin (NSC-65346).

J A Cavins, T C Hall, K B Olson, C L Khung, J Horton, J Colsky, R K Shadduck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4318252

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  7 in total

1.  Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

Authors:  Nathan G Dolloff; Joshua E Allen; David T Dicker; Nicole Aqui; Dan Vogl; Jozef Malysz; Giampaolo Talamo; Wafik S El-Deiry
Journal:  Mol Cancer Ther       Date:  2012-09-10       Impact factor: 6.261

2.  A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.

Authors:  Ryan P Bennett; Courtney L Finch; Elena N Postnikova; Ryan A Stewart; Yingyun Cai; Shuiqing Yu; Janie Liang; Julie Dyall; Jason D Salter; Harold C Smith; Jens H Kuhn
Journal:  Viruses       Date:  2020-12-31       Impact factor: 5.048

3.  Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties.

Authors:  Ryan P Bennett; Elena N Postnikova; Brett P Eaton; Yingyun Cai; Shuiqing Yu; Charles O Smith; Janie Liang; Huanying Zhou; Gregory A Kocher; Michael J Murphy; Harold C Smith; Jens H Kuhn
Journal:  JCI Insight       Date:  2022-01-11

Review 4.  CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.

Authors:  Jędrzej Borowczak; Krzysztof Szczerbowski; Navid Ahmadi; Łukasz Szylberg
Journal:  Med Oncol       Date:  2022-01-29       Impact factor: 3.064

5.  ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Authors:  Luke H Stockwin; Sherry X Yu; Howard Stotler; Melinda G Hollingshead; Dianne L Newton
Journal:  BMC Cancer       Date:  2009-02-20       Impact factor: 4.430

Review 6.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

7.  Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.

Authors:  Ligia I Bastea; Laeticia M A Hollant; Heike R Döppler; Elizabeth M Reid; Peter Storz
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.